Silencing of the PTEN tumor‐suppressor gene in anaplastic thyroid cancer
- 3 May 2002
- journal article
- research article
- Published by Wiley in Genes, Chromosomes and Cancer
- Vol. 35 (1), 74-80
- https://doi.org/10.1002/gcc.10098
Abstract
Germline mutations in the tumor‐suppressor gene PTEN (MMAC1, TEP1) are found in Cowden syndrome, which predisposes to hamartomas, breast cancer, trichilemmomas, and thyroid tumors of follicular epithelium. PTEN has also been found to be somatically deleted, mutated, and/or silenced in various sporadically occurring cancers such as glioblastoma, breast cancer, kidney cancer, malignant melanoma, and endometrial cancer. Loss or reduction of PTEN protein expression as well as inappropriate subcellular compartmentalization is seen in non‐medullary thyroid cancers. However, although allelic loss of the PTEN locus in 10q23.3 is frequently seen, this is not coupled with mutations in the PTEN gene. To approach further the frequency and mechanism behind PTEN silencing, we screened a panel of 87 sporadic thyroid tumors for PTEN mRNA expression, including 14 anaplastic carcinomas, 37 follicular carcinomas, 21 atypical adenomas, and 15 ordinary adenomas. Complete loss of PTEN mRNA expression was evident in six of the tumors, including four anaplastic carcinomas, one widely invasive carcinoma, and one ordinary adenoma. The transcriptional silencing of PTEN was significantly associated with the anaplastic subtype, suggesting that PTEN is involved in the carcinogenesis of highly malignant or late‐stage thyroid cancers, whereas this particular mechanism appears to be of minor importance in differentiated follicular thyroid tumors. No association was observed between the expression, loss of heterozygosity, and mutation status in the 33 cases in which these parameters were compared. This indicates that PTEN silencing is a result of a wide variety of epigenetic and/or structural silencing mechanisms rather than a consequence of structural biallelic inactivation of the classical type. Furthermore, the high rate of alterations in the 10q23 region might indicate the presence of an as‐yet unknown tumor‐suppressor gene with an important role in the development of thyroid tumors.Keywords
Funding Information
- Swedish Cancer Foundation
- Torsten and Ragnar Söderberg Foundations
- Milton Foundation
- Stockholm County Council
- Cancer Society in Stockholm
This publication has 22 references indexed in Scilit:
- Epigenetic PTEN Silencing in Malignant Melanomas without PTEN MutationThe American Journal of Pathology, 2000
- PAX8-PPAR γ 1 Fusion in Oncogene Human Thyroid CarcinomaScience, 2000
- Differential Nuclear and Cytoplasmic Expression of PTEN in Normal Thyroid Tissue, and Benign and Malignant Epithelial Thyroid TumorsThe American Journal of Pathology, 2000
- Transcriptional analysis of the PTEN/MMAC1 pseudogene, ΨPTENOncogene, 1999
- Genetic and epigenetic alterations of the cyclin-dependent kinase inhibitors p15INK4b and p16INK4a in human thyroid carcinoma cell lines and primary thyroid carcinomasCancer, 1998
- Negative Regulation of PKB/Akt-Dependent Cell Survival by the Tumor Suppressor PTENCell, 1998
- A highly conserved processed PTEN pseudogene is located on chromosome band 9p21Oncogene, 1998
- Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndromeNature Genetics, 1997
- Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancersNature Genetics, 1997
- PTEN , a Putative Protein Tyrosine Phosphatase Gene Mutated in Human Brain, Breast, and Prostate CancerScience, 1997